Skip to main content
SpringerLink
Log in

Clinical Significance of Cellular Drug Resistance in Childhood Leukemia

  • Conference paper
Chemosensitivity Testing in Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 161))

Abstract

Cellular drug resistance is an important determinant of the response to chemotherapy, and its precise measurement may have clinical relevance. Potential applications are: prognostic factor for risk-group stratification, tailored chemotherapy for subgroups or individual patients with a specific cellular drug resistance profile, determination of cross-resistance patterns, study of drug interactions, study of resistance modulation or circumvention, selection of patients for phase II studies and screening for the cytotoxicity of novel compounds. The colorimetric 4-day MTT assay is a frequently used method. However, a distinction between malignant and non-malignant cells cannot be made, which should be taken into account. In the case of a relatively high percentage of contaminating non-malignant cells, the differential staining cytotoxicity (DiSC) assay can be used. The MTT assay’s technical success percentage is about 80% for fresh ALL and AML samples. For methotrexate (MTX) a different assay must be used, such as the thymidylate synthase inhibition assay (TSIA). The MTT assay measures the number of living cells that survived drug exposure. Therefore, the effect of many if not most drugs to induce leukemia cell death by apoptosis is also included. This review mainly summarizes the data on cellular drug resistance in childhood leukemia, as obtained by the MTT assay and TSIA, in our laboratory in Amsterdam. These data clearly demonstrate the significant relation between in vitro cellular drug resistance and clinical and cell biological features and short- and long-term clinical outcome in childhood leukemia. In conclusion, cellular drug resistance testing provides clinically relevant information that can be available within 1 week and can be performed successfully in the vast majority of leukemia samples. The data are more and more being used and being considered for use in clinical trials in leukemia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Agthe AG, Dörffel W, Neuendank A, Hartmann R, Brühmüller S, Klumper E, Pieters R, Veerman AJP, Henze G (1997) Tailored therapy for relapsed or refractory childhood acute lymphoblastic leukemia. In: Pieters R, Kaspers GJL, Veerman AJP (eds) Drug resistance in leukemia and lymphoma II. Harwood Academic, Amsterdam, pp 51–57

    Google Scholar 

  • Asselin BL, Kreissman S, Coppola DJ, Bernal SD, Leavitt PR, Gelber RD, Sallan SE, Cohen HJ (1999) Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 21:6–12

    Article  PubMed  CAS  Google Scholar 

  • Bresters D, Broekhuizen R, Jimeno J, Faircloth GT, Kaspers GJL (2002a) Different cytotoxic activity in vitro of aplidine in pediatric leukemic and normal bone marrow and blood samples. Proc Am Assoc Cancer Res 43:924 (#4579)

    Google Scholar 

  • Bresters D, Broekhuizen R, Jimeno J, Faircloth GT, Kaspers GJL (2002b) Lack of in vitro cross-resistance between Aplidine and other drugs in childhood leukemia and normal bone marrow and blood samples. Proc Am Assoc Cancer Res 43:925 (#4583)

    Google Scholar 

  • Cortazar P, Johnson BE (1999) Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 17:1625–1631

    PubMed  CAS  Google Scholar 

  • Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, Henze G, Jurgens H, Kabisch H, Havers W, Reiter A, Kluba U, Niggli F, Gadner H (2001) Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol 19:2705–2713

    PubMed  CAS  Google Scholar 

  • De Haas V, Kaspers GJL, Oosten L, Bresters D, Wijkhuijs AJM, Van Der Berg H, Van Der Schoot CE (2001) In vitro resistance to prednisolone is related to minimal residual disease (MRD) after induction therapy in childhood acute lymphoblastic leukemia (ALL). Leukemia 15:510 (abstract P62)

    Google Scholar 

  • Den Boer ML, Kapaun P, Pieters R, Kazemier KM, Janka-Schaub GE, Veerman AJP (1999) Myeloid antigen co-expression in childhood acute lymphoblastic leukaemia: relationship with in vitro drug resistance. Br J Haematol 105:876–882

    Article  Google Scholar 

  • D’Haens EJ, Veerman AJP (1998) Complete remission in a boy with treatment refractory acute lymphoblastic leukemia based on in vitro drug resistance testing with the MTT assay (in Dutch, English abstract). Tijdschr Kindergeneeskd 66:129–132

    Google Scholar 

  • Dübbers A, Würthwein G, Müller HJ, Schulze-Westhoff P, Winkelhorst M, Kurzknabe E, Lanvers C, Pieters R, Kaspers GJL, Creutzig U, Ritter J, Boos J (2000) Asparagine synthetase activity in pediatric acute leukaemias: AML-M5 subtype shows lowest activity. Br J Haematol 109:427–429

    Article  PubMed  Google Scholar 

  • Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499–505

    Article  PubMed  CAS  Google Scholar 

  • Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Hammond GD, Bleyer WA (2000) Children’s Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995. Leukemia 14:2223–2233

    Article  PubMed  CAS  Google Scholar 

  • Haarman EG, Kaspers GJL, Pieters R, Rottier MMA, Veerman AJP (2001a) Cell death regulator expression versus glucocorticoid resistance in childhood acute lymphoblastic leukemia. Leukemia 15:495 (abstract no. O56)

    Google Scholar 

  • Haarman EG, Kaspers GJL, Pieters R, Rottier MMA, Veerman AJP (2001b) Modulation of glucocorticoid resistance in childhood acute lymphoblastic leukemia; preliminary results. Haematol Blood Transf 40:236–243

    CAS  Google Scholar 

  • Haarman EG, Kaspers GJL, Pieters R, Rottier MMA, Veerman AJP (2001c) A comparison of the antileukemic activity in vitro of cortivazol, prednisolone and dexamethasone in childhood leukemia. Ann Hematol 80 [Suppl II]:S31 (abstract)

    Google Scholar 

  • Hongo T, Fujii Y, Yajima S (1993) In vitro chemosensitivity of childhood leukemic cells and the clinical value of assay directed chemotherapy. In: Kaspers GJL et al. (eds) Drug resistance in leukemia and lymphoma I. Chur, Harwood, pp 313–319

    Google Scholar 

  • Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R (1997) In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 89:2959–2965

    PubMed  CAS  Google Scholar 

  • Hongo T, Yamada S, Yajima S, Watanabe C, Fujii Y, Kawasaki H, Yazaki M, Hanada R, Horokoshi Y (1999) Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, l-asparaginase, and vincristine in childhood acute lymphoblastic leukemia. Int J Hematol 70:268–277

    PubMed  CAS  Google Scholar 

  • Hurwitz CA, Silverman LB, Schorin MA, Clavell LA, Dalton VK, Glick KM, Gelber RD, Sallan SE (2000) Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 88:1964–1969

    Article  PubMed  CAS  Google Scholar 

  • Ito C, Evans WE, McNinch L, Coustan-Smith E, Mahmoud H, Pui CH, Campana D (1996) Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 14:2370–2376

    PubMed  CAS  Google Scholar 

  • Jones B, Freeman AI, Shuster J, et al. (1991) Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphoblastic leukemia. Med Pediatr Oncol 19:269–275

    Article  PubMed  CAS  Google Scholar 

  • Kaspers GJL, Pieters R, Van Zantwijk CH, De Laat E, De Waal FC, Van Wering ER, Veerman AJP (1991) In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 64:469–474

    Article  PubMed  CAS  Google Scholar 

  • Kaspers GJL, Veerman AJP, Pieters R, Broekema GJ, Huismans DR, Kazemier KM, Loonen AH, Rottier MMA, Van Zantwijk CH, Hählen K, Van Wering ER (1994a) Mononuclear cells contaminating leukemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer 70:1047–1052

    Article  PubMed  CAS  Google Scholar 

  • Kaspers GJL, Pieters R, Klumper E, Van Zantwijk CH, Hählen K, De Waal FC, Van Wering ER, Veerman AJP (1994b) In vitro cytotoxicity of mitoxantrone, daunorubicin, and doxorubicin in untreated childhood acute leukemia. Leukemia 8:24–29

    PubMed  CAS  Google Scholar 

  • Kaspers GJL, Kardos G, Pieters R, Van Zantwijk CH, Klumper E, Hählen K, De Waal FC, Van Wering ER, Veerman AJP (1994c) Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report. Leukemia 8:1224–1229

    PubMed  CAS  Google Scholar 

  • Kaspers GJL, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP (1995a) Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leukemia Lymphoma 19:407–417

    Article  PubMed  CAS  Google Scholar 

  • Kaspers GJL, Smets LA, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP (1995b) Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: Results of an in vitro study. Blood 85:751–756

    PubMed  CAS  Google Scholar 

  • Kaspers GJL, Pieters R, Van Zantwijk CH, Hählen K, Van Wering ER, Veerman AJP (1995c) Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leuk Res 19:175–181

    Article  PubMed  CAS  Google Scholar 

  • Kaspers GJL, Veerman AJP, Popp-Snijders C, Lomecky M, Van Zantwijk CH, Swinkels LMJW, Van Wering ER, Pieters R (1996) Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 27:114–121

    Article  PubMed  CAS  Google Scholar 

  • Kaspers GJL, Veerman AJP, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER, Van Der Does-Van Den Berg A (1997a) In vitro cellular drug resistance and prognosis in childhood acute lymphoblastic leukemia. Blood 90:2723–2729

    PubMed  CAS  Google Scholar 

  • Kaspers GJL, Pieters R, Veerman AJP (1997b) Glucocorticoid resistance in childhood leukemia. Int J Pediatr Hematol Oncol 4:583–596

    Google Scholar 

  • Kaspers GJL, Pieters R, Van Zantwijk CH, Van Wering ER, Van Der Does-Van Den Berg A, Veerman AJP (1998) Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood 92:259–266

    PubMed  CAS  Google Scholar 

  • Kaspers GJL, Zwaan ChM, Veerman AJP, Rots MG, Pieters R, Bucsky P, Domula M, Göbel U, Graf N, Havers W, Jorch N, Kabisch K, Spaar H-J, Ritter J, Creutzig U (1999) Cellular drug resistance in acute myeloid leukemia: literature review and preliminary analysis of an ongoing collaborative study. Klin Pädiatr 211:239–244

    Article  PubMed  CAS  Google Scholar 

  • Kaspers GJL, Litvinova E, Hubeek I, Haarman EG, Huismans DR, Peters GJ, Veerman AJP (2001a) Increased in vitro cytotoxicity of cytarabine when combined with fludarabine towards childhood acute myeloid leukemia cells. Leukemia 15:497 (abstract P08)

    Google Scholar 

  • Kaspers GJL (2001b) Pediatric leukemia in the new millennium (editorial). Expert Rev Anticancer Ther 1:1–2

    Article  PubMed  CAS  Google Scholar 

  • Klumper E, Pieters R, Veerman AJP, Huismans DR, Loonen AH, Hählen K, Kaspers GJL, Van Wering ER, Hartmann R, Henze G (1995a) Cellular drug resistance in children with relapsed and refractory acute lymphoblastic leukemia. Blood 86:3861–3868

    PubMed  CAS  Google Scholar 

  • Klumper E, Pieters R, Kaspers GJL, Huismans DR, Loonen AH, Rottier MMA, Van Wering ER, Van Der Does-Van Den Berg A, Hählen K, Creutzig U, Veerman AJP (1995b) In vitro chemosensitivity testing assessed with the MTT assay in childhood acute non-lymphoblastic leukemia. Leukemia 9:1864–1869

    PubMed  CAS  Google Scholar 

  • Klumper E, Pieters R, Den Boer ML, Huismans DR, Loonen AH, Veerman AJP (1995c) In vitro anthracycline cross-resistance patterns in childhood acute lymphoblastic leukemia. Br J Cancer 71:1188–1193

    Article  PubMed  CAS  Google Scholar 

  • Klumper E, Ossenkoppele G, Pieters R, Huismans DR, Loonen AH, Rottier A, Westra G, Veerman AJP (1996) In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. Br J Haematol 93:903–910

    Article  PubMed  CAS  Google Scholar 

  • Krance RA, Hurwitz CA, Head DR, Raimondi SC, Behm FG, Crews KR, Srivastava DK, Mahmoud H, Roberts WM, Tong X, Blakley RL, Ribeiro RC (2001) Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 19:2804–2811

    PubMed  CAS  Google Scholar 

  • Mattano LA Jr, Sather HN, Trigg ME, Nachman JB (2000) Osteonecrosis as a complication of treating acute lymphoblastic leukemia n children: a report from the Children’s Cancer group. J Clin Oncol 18:3262–3272

    PubMed  Google Scholar 

  • Mauritz R, Bekkenk MW, Rots MG, Pieters R, Mini E, Van Zantwijk CH, Veerman AJP, Peters GJ, Jansen G (1998) Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells. Clin Cancer Res 4:2399–2410

    PubMed  CAS  Google Scholar 

  • Parker AN, Hutchinson RM, Chapman CS, Bosanquet AG (1992) Effective treatment of relapsed acute myeloid leukaemia with drugs chosen by DiSC assay. Br J Haematol 81:455–456

    Article  PubMed  CAS  Google Scholar 

  • Pieters R, Huismans DR, Leyva A, Verman AJP (1988) Adaptation of the rapid automated tetrazolium dye based MTT assay for chemosensitivity testing in childhood leukemia. Cancer Lett 41:323–332

    Article  PubMed  CAS  Google Scholar 

  • Pieters R, Huismans DR, Leyva A, Veerman AJP (1989) Comparison of a rapid automated tetrazolium based (MTT) assay with a dye exclusion assay for chemosensitivity testing in childhood leukemia. Br J Cancer 59:217–220

    Article  PubMed  CAS  Google Scholar 

  • Pieters R, Loonen AH, Huismans DR, Broekeka GJ, Dirven MWJ, Heyenbrok MW, Hählen K, Veerman AJP (1990) In vitro drug sensitivity of cells from children with leukemia using the MTTassay with improved culture conditions. Blood 76:2327–2336

    PubMed  CAS  Google Scholar 

  • Pieters R, Huismans DR, Loonen AH, Hahlen K, Van Der Does-Van Den Berg A, Van Wering ER, Veerman AJP (1991) Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 338:399–403

    Article  PubMed  CAS  Google Scholar 

  • Pieters R, Klumper E, Kaspers GJL, Veerman AJP (1997) Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Crit Rev Hematol/Oncol 25:11–26

    Article  CAS  Google Scholar 

  • Pieters R, Den Boer ML, Durian M, Janka G, Schmiegelow K, Kaspers GJL, Van Wering ER, Veerman AJP (1998) Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia — implications for treatment of infants. Leukemia 12:1344–1348

    Article  PubMed  CAS  Google Scholar 

  • Preisler HD, Gopal V (1994) Regrowth resistance in leukemia and lymphoma: the need for a new system to classify treatment failure and for new approaches to treatment. Leuk Res 18:149–160

    Article  PubMed  CAS  Google Scholar 

  • Pui C-H, Evans WE (2000) Acute lymphoblastic leukemia in children. Curr Opin Oncol 12:3–12

    Article  PubMed  CAS  Google Scholar 

  • Ramakers-Van Woerden NL, Pieters R, Loonen AH, Hubeek I, Van Drunen E, Beverloo HB, Slater RM, Harbott J, Seyfarth J, Van Wering ER, Hählen K, Schmiegelow K, Janka-Schaub GE, Veerman AJP (2000) TEL/AML1 gene fusion is related to in vitro drug sensitivity for l-asparaginase in childhood acute lymphoblastic leukemia. Blood 96:1094–1099

    PubMed  CAS  Google Scholar 

  • Ramakers-van Woerden NL, Pieters R, Rots MG, Kaspers GJL, Van Wering ER, Loonen AH, Slater RM, Harbott J, Schmiegelow K, Janka-Schaub GE, Veerman AJP (2001a) Ploidy status and drug resistance profiles in childhood acute lymphoblastic leukemia: an analysis of 425 cases. Leukemia 15:506 (abstract no. P45)

    Google Scholar 

  • Ramakers-van Woerden NL, Pieters R, Slater RM, Loonen AH, Beverloo HB, Van Drunen E, Heyman M, Moreno TC, Rots MG, Van Wering ER, Kamps WA, Janka-Schaub GE, Veerman AJP (2001b) In vitro drug resistance and prognostic impact of p16INK4A/p15INK4B deletions in childhood T-cell acute lymphoblastic leukaemia. Br J Haematol 112:680–690

    Article  PubMed  CAS  Google Scholar 

  • Rots MG, Pieters R, Kaspers GJL, Van Zantwijk CH, Noordhuis P, Mauritz R, Veerman AJP, Jansen G, Peters GJ (1999a) Differential methotrexate resistance in childhood T-versus common/pre-B acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay. Blood 93:1067–1074

    PubMed  CAS  Google Scholar 

  • Rots MG, Pieters R, Peters GJ, Van Zantwijk CH, Mauritz R, Noordhuis P, Willey JC, Hählen K, Creutzig U, Janka-Schaub G, Kaspers GJL, Veerman AJP, Jansen G (1999b) Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates. Blood 94:3121–3128

    PubMed  CAS  Google Scholar 

  • Rots MG, Pieters R, Kaspers GJL, Veerman AJP, Peters GJ, Jansen G (2000) Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia. Br J Haematol 110:791–800

    Article  PubMed  CAS  Google Scholar 

  • Rots MG, Pieters R, Peters GJ, Kaspers GJL, Van Zantwijk CH, Noordhuis P, Voorn DA, Van Wering ER, Creutzig U, Veerman AJP, Jansen G (2001) A possible role for methotrexate in the treatment of childhood acute myeloid leukemia in general, and for acute monocytic leukemia in particular. Eur J Haematol 37:492–498

    CAS  Google Scholar 

  • Sargent JM, Williamson CJ, Taylor CG, Pieters R, Peters GJ, Kaspers GJL (2001) Aphidicolin decreases in vitro resistance to ara-C in childhood acute leukaemia. Leukemia 15:497 (abstract P09)

    Google Scholar 

  • Schmiegelow K, Nyvold C, Seyfarth J, Pieters R, Knabe N, Rottier N, Ryder LP, Madsen HO, Kaspers GJL (2001) Post-induction residual disease in childhood acute lymphoblastic leukemia quantified by PCR is related to in vitro prednisolone resistance. Leukemia 15:1066–1071

    Article  PubMed  CAS  Google Scholar 

  • Sievers EL, Radich JP (2000) Detection of minimal residual disease in acute leukemia. Curr Opin Hematol 7:212–216

    Article  PubMed  CAS  Google Scholar 

  • Stevens RF, Hann IM, Wheatley K, Gray RG (1998) Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council’s 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 101:130–140

    Article  PubMed  CAS  Google Scholar 

  • Van Dongen JJM, Seriu T, Panzer-Grumayer ER, et al. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukemia. Lancet 352:1731–1738

    Article  PubMed  Google Scholar 

  • Veerman AJP, Pieters R (1990a) Drug sensitivity assays in leukaemia and lymphoma. Br J Haematol 74:381–384

    Article  PubMed  CAS  Google Scholar 

  • Veerman AJP, Hählen K, Kamps WA, Van Leeuwen EF, De Vaan GAM, Van Wering ER, Van der Does-Van Den Berg A, Solbu G, Suciu S (1990b) Dutch Childhood Leukemia Study Group: Early results of study ALL-VI (1984–1988). Haematol Blood Transf 33:473–477

    CAS  Google Scholar 

  • Veerman AJP, Hählen K, Kamps WA, Van Leeuwen EF, De Vaan GAM, Solbu G, Suciu S Van Wering ER, Van der Does-Van Den Berg A (1996) High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14:911–918

    PubMed  CAS  Google Scholar 

  • Zwaan ChM, Kaspers GJL, Pieters R, Huismans DR, Van Wering ER, Janka-Schaub GE, Creutzig U, Henze G, Veerman AJP (2000a) Circumvention of cytarabine resistance by 2-chlorodeoxyadenosine in pediatric acute myeloid and acute lymphoblastic leukemia: an in vitro study. Blood 96 (11, part 1):307a (abstract)

    Google Scholar 

  • Zwaan ChM, Kaspers GJL, Pieters R, Ramakers-Van Woerden NL, Den Boer ML, Wünsche R, Rottier MMA, Hählen K, Van Wering ER, Janka-Schaub GE, Creutzig U, Veerman AJP (2002b) Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 96:2879–2886

    Google Scholar 

  • Zwaan ChM, Kaspers GJL, Pieters R, Hählen K, Janka-Schaub GE, Van Zantwijk CH, Huismans DR, De Vries E, Rots MG, Peters GJ, Jansen G, Creutzig U, Veerman AJP (2002a) Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 99:245–251

    Article  PubMed  CAS  Google Scholar 

  • Zwaan ChM, Kaspers GJL, Pieters R, Hählen K, Huismans DR, Zimmermann M, Harbott J, Släter RM, Creutzig U, Veerman AJP (2002b) Cellular drug resistance is related to chromosomal abnormalities in childhood AML. Blood (in press)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology/Oncology, VU University Medical Center, De Boelelaan 1117, 1081, Amsterdam, The Netherlands

    G. J. L. Kaspers

Authors
  1. G. J. L. Kaspers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. J. P. Veerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hautklinik und Poliklinik, Universitätskliniken des Saarlandes, 66421, Homburg/Saar, Germany

    Uwe Reinhold  & Wolfgang Tilgen  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Kaspers, G.J.L., Veerman, A.J.P. (2003). Clinical Significance of Cellular Drug Resistance in Childhood Leukemia. In: Reinhold, U., Tilgen, W. (eds) Chemosensitivity Testing in Oncology. Recent Results in Cancer Research, vol 161. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-19022-3_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-19022-3_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62412-4

  • Online ISBN: 978-3-642-19022-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation